Search
Results: 2
Tumour Necrosis Factor Inhibitor monotherapy versus combination therapy for the treatment of psoriatic arthritis
Matthew Thomas, Gavin Shaddick, Rachel Charlton, Charlotte Cavill, Richard Holland, Florenzo Iannone, Giovanni Lapadula, Simona Lopriore, Jakub Zavada, Michal Uher, Karel Pavelka, Lenka Szczukova, Prodromos Sidiropolous, Irini Flouri, Alexandros Drosos, Burkhard Möller, Michael Nissen, Rüdiger Müller, Almut Scherer, Neil McHugh, Alison Nightingale
Jan 01, 2021
Objective
To investigate whether tumour necrosis factor inhibitor (TNFi) combination therapy with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) is more effective for psoriatic arthritis (PsA)...
To investigate whether tumour necrosis factor inhibitor (TNFi) combination therapy with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) is more effective for psoriatic arthritis (PsA)...
Tumour Necrosis Factor Inhibitor monotherapy versus combination therapy for the treatment of psoriatic arthritis
Matthew Thomas, Gavin Shaddick, Rachel Charlton, Charlotte Cavill, Richard Holland, Florenzo Iannone, Giovanni Lapadula, Simona Lopriore, Jakub Zavada, Michal Uher, Karel Pavelka, Lenka Szczukova, Prodromos Sidiropolous, Irini Flouri, Alexandros Drosos, Burkhard Möller, Michael Nissen, Rüdiger Müller, Almut Scherer, Neil McHugh, Alison Nightingale
Jan 01, 2021
Objective
To investigate whether tumour necrosis factor inhibitor (TNFi) combination therapy with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) is more effective for psoriatic arthritis (PsA)...
To investigate whether tumour necrosis factor inhibitor (TNFi) combination therapy with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) is more effective for psoriatic arthritis (PsA)...